<DOC>
	<DOC>NCT02788565</DOC>
	<brief_summary>Data from this study will contribute additional knowledge regarding patient outcomes and direct somatostatin analogue (SSA) treatment related costs in clinical practice in the Nordic countries. Such knowledge can be of importance in a treatment decision, decision support for development of care, follow up and training of both patients and primary care nurses.</brief_summary>
	<brief_title>Quality of Life, Treatment Experience and Cost of Treatment With Somatostatin Analogues in Patients With Gastroenteropancreatic Neuroendocrine Tumours</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Somatostatin</mesh_term>
	<criteria>Signed informed consent Diagnosed with a Gastroenteropancreatic Neuroendocrine Tumour (GEPNET) and treated with SSA for at least three months but not more than 3 years GEPNET proliferation index Ki 67 &lt;10% Over 18 years of age No specific exclusion criteria defined</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>